[Skip to Content]
[Skip to Content Landing]
Research Letter
August 2018

Timolol Eyedrops in the Treatment of Acute Migraine Attacks: A Randomized Crossover Study

Author Affiliations
  • 1University of Missouri–Kansas City School of Medicine, Kansas City
JAMA Neurol. 2018;75(8):1024-1025. doi:10.1001/jamaneurol.2018.0970

Several oral β-blockers are US Food and Drug Administration–approved for migraine prophylaxis, but their gradual absorption and modification by first-pass metabolism delays effective plasma levels for hours to days, limiting their use in acute migraines.1 Timolol eyedrops provide a rapid route of delivery with the maximum plasma concentration achieved within 15 minutes of administration.2,3 This pharmacokinetic advantage supports a potential role for timolol eyedrops in managing acute migraine.4,5